Crimson BioPharm

Ownership

Private

Therapeutic Areas

Oncology

Stage

Phase 1

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Modalities

Small molecule drug

Crimson BioPharm General Information

Currently conducting Phase 1 clinical trials for CM-93, an EGFR antagonist for recurrent glioblastoma as of April 2025.

Contact Information

Website

https://www.ventureradar.com/similar/Crimson%20Biopharm/a42f7d85-679e-4cc0-aec6-ea6a9de0fbf4

Primary Industry

Biotech

Corporate Office

Brookline, Massachusetts
United States

Drug Pipeline

CM93

Phase 1

Indications: Lorem ipsum dolor sit

Modality: Lorem ipsum

Drug Asset 2

Phase X

Indications: Lorem ipsum dolor sit

Modality: Lorem ipsum

Drug Asset 3

Phase X

Indications: Lorem ipsum dolor sit

Modality: Lorem ipsum

For full access to Crimson BioPharm's pipeline data

Key Partnerships

No partnerships listed

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Crimson BioPharm Funding

No funding data available

Early Stage VC (Series A)	04-Jun-2020	$38M	Completed	Phase 1
Seed Round	12-Feb-2019	$8.5M	Completed	Startup

Interested in comprehensive profile data?

We'll help you find what you need

To view Crimson BioPharm's complete valuation and funding history, request access »

Crimson BioPharm Financial Metrics